Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Numab's Pipeline To Benefit From Intarcia Licensing Its ND016

Executive Summary

Privately held Swiss immunology and immuno-oncology specialist Numab Therapeutics has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics, and will use the proceeds to advance its own drug pipeline, its co-founder tells Scrip.


Related Content

Deal Watch: Oncternal Goes Public Via Reverse Merger With GTx


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts